Vitro Diagnostics Enters Contract to Develop Stem Cell-Derived Food

GOLDEN, Colo., Jul 27, 2010 — Vitro Diagnostics, Inc. announced that it has entered into a contract with Mokshagundam Biotechnologies, a private research organization established to develop alternative meat sources, to develop cell culture medium for use in exploration of alternative food sources derived from stem cells. Cell culture media is a complex solution of salts and nutrients designed to support growth of living cells; each type of cell requires specific components within the media to optimize its growth. This project intends to utilize cultured marine invertebrates, nourished by medium only as a source of food for fish initially and possibly domestic animals. The initial target organism has a well-defined stem cell system that results in regeneration of body parts following amputation, and continuous growth of the organism. Vitro is to provide prototype media to support expansion of these marine organisms without requiring additional food sources. Successful development of such a product could lead to commercial production of food sources that rely on cell culture technology utilizing cell culture medium as the primary consumable product in the manufacturing process. This technology may also be expanded to include animal and human food sources using stem cells that give rise to muscle cells, which is the primary ingredient of meat. The manufacture of stem cell-derived meat allows complete control of the meat with regard to chemical content and the elimination of contaminants such as E. coli, hormones, antibiotics antibioticstore, pesticides and the cause of “Mad Cow Disease.” Additional substances may be added to enhance taste and nutritional value.

Dr. Jim Musick, Vitro’s CEO, said, “We are pleased to be involved with this ground breaking opportunity to extend stem cell technology to development of alternative food sources. Cellular immortality as reflected in continual stem cell proliferation (self-renewal) has potential to provide limitless cells that when differentiated to muscle, for example, become the primary ingredient of meat. This reflects the basis of alternative food derived from stem cells that is now being developed. We intend to use our expertise in stem cell media development and commercial manufacture to provide appropriate media formulations to support this nascent technology. Our VITROGROW(TM) Brand of stem cell media has been demonstrated to result in superior performance to competing products in the growth of human adult stem cells and is now utilized in high performance, bioluminescent test kits (Lumenesc-Hu(TM) and LumiSTEM(TM)) for measuring the quality and potency of mesenchymal and induced-pluripotent stem cells. We anticipate contributing to this exciting new field and plan to further develop cellular immortalization procedures that may be crucial to economic production of stem cell-derived meat.”

Kedar Challakere, MD, of Mokshagundam Biotechnologies stated, “The in vitro meat products developed thus far have used fetal bovine serum with which to grow their stem cells. The product currently being developed through our contract with Vitro is a synthetic, animal free medium which is anticipated to replace a living organism, the brine shrimp, from the food chain of aquatic creatures.”

About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc., dba Vitro Biopharma (OTCBB: VODG;, owns US patents for production of a fertility drug, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro’s mission is “Harnessing the Power of Cells(TM)” for the advancement of regenerative medicine to its full potential. Vitro also owns pending US patents for stem cell therapy of cancer, generation of pluripotent stem cells and is continuously developing patentable cell lines and technologies. Vitro operates within a high technology and regulatory compliant manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells “Tools for Stem Cell and Drug Development(TM)”, including human mesenchymal stem cells and derivatives, the VITROGROW(TM) Brand of optimized media for sustained self-renewal, lineage-specific differentiation and products supporting induced pluripotent stem cell and cancer research. Vitro recently formed a strategic alliance with HemoGenix(R) (, a privately held life sciences company located in Colorado Springs, Colorado, that was founded in 2000 by Ivan N. Rich, Ph.D., an internationally recognized researcher in the field of developmental, experimental and applied clinical hematology. Through this alliance, new stem cell testing products were recently launched allowing state-of-the-art testing of mesenchymal and induced-pluripotent stem cells.

Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.